Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

1. Ludvik, B.
2. Giorgino, F.
3. Jódar, E.
4. Frias, J.P.
5. Fernández Landó, L.
6. Brown, K.
7. Bray, R.
8. Rodríguez, Á.